



Novel Psychedelics

for Treating Addictions, Obesity & Mental Health

Corporate Presentation | October 2024

➤ NASDAQ: **CMND**

➤ FSE: **CWY0**

www.Clearmindmedicine.com

Disclaimer and Forward-Looking Statements

All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." Forward-looking statements contained in this presentation include, but are not limited to, statements regarding Clearmind Medicine Inc. (the "Company") strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses financial plans, its project pipeline, its expected revenue models, the potential of its technology, its strategy, market potential for its technology and its future growth. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed or indicated by the forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

This presentation includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information. Although we are responsible for all of the disclosures contained in this presentation, including such statistical, market and industry data, we have not independently verified any of the data from third-party sources, nor have we ascertained the underlying economic assumptions relied upon therein. In addition, while we believe the market opportunity information included in this presentation is generally reliable and is based on reasonable assumptions, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by us.

This presentation does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any of our securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offering of securities can only be made in compliance with applicable securities laws.

Trade names, trademarks and service marks of third parties in this presentation are the property of their respective holders.

About Clearmind

Why Psychedelics?

Psychedelic compounds are increasingly being studied and many believe represent the future for treatment of a variety of mental health disorders.

Clearmind's solutions for addiction, especially alcoholism and obesity, hold the potential to better the lives of millions around the world.



Nasdaq public company
NASDAQ:CMND FSE:CWYO



Pharmaceutical company developing patent-protected psychedelic medicines to solve widespread mental health disorders



Initially targeting addiction market, including alcoholism and obesity



IND clearance from FDA
Clinical trials expected to commence in 2024




19 patents families.
29 granted in the USA and other major jurisdictions



Partnership with leading universities & KOLs

Pipeline



Alcohol Use Disorder

Clearmind's flagship treatments are focused on Alcohol Use Disorder (AUD), which is extremely common. AUD describes a person's **inability to restrict their alcohol consumption**, despite negative social, occupational, or health consequences.

Alcohol consumption contributes to **2.6 million deaths (accounting for 4.7% of all deaths)** each year globally

In addition to disabilities and poor health
——— WORLD HEALTH ORGANIZATION¹ ———

Alcohol abuse is among the biggest killers in the world, and a leading preventable cause of death in the U.S.²

Alcohol is the most common substance used among people 12 and older in the United States²

The economic costs of alcohol consumption were estimated to be \$1,306 per adult globally³

¹ <https://www.who.int/news/item/25-06-2024-over-3-million-annual-deaths-due-to-alcohol-and-drug-use-majority-among-men>

² <https://www.cdc.gov/alcohol/facts-stats/index.html>

³ Manthey J, Hassan SA, Carr S, Kilian C, Kuitunen-Paul S, Rehm J. What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study. Pharmacoeconomics. 2021 Jul;39(7):809-822. doi: 10.1007/s40273-021-01031-8. Epub 2021 May 10. PMID: 33970445; PMCID: PMC8200347.

The Opportunity

The **yearly cost** of excessive alcohol use in the US was almost **\$250 billion** in 2010

<https://pubmed.ncbi.nlm.nih.gov/26477807/>

\$28 billion of which has been accounted for as healthcare costs

https://www.cdc.gov/alcohol/images/real_cost_alcohol_use.jpg

1 Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis, 2014.
2 Winslow BT, Onysko M, Hebert M. Medications for Alcohol Use Disorder. Am Fam Physician. 2016 Mar 15;93(6):457-65.

Only 4 FDA approved medicines for AUD

	Approved by FDA	Average \$/Month
Antabuse Disulfiram	1949	\$42
Campral Acamprosate	2004	\$125
ReVia Naltrexone	1994	\$205
Vivitrol Naltrexone	2006	\$1000

Existing medicines are expensive, have low efficacy (less than 30%)^{1,2} , and low patient compliance due to side effects.

\$400.4 million Vivitrol sales (2023)

Clearmind's solution is its flagship proprietary molecule: **MEAI** or 5-Methoxy-2-aminoindane



1
MEAI is a non-hallucinogenic psychoactive molecule


2
Holds the potential to **change the lives** of millions who struggle with addictions

3
In **recreational use**, exerted a **reduced desire** to consume alcoholic beverages with a euphoric **alcohol-like** experience

4
Believed to impart a feeling of satisfaction, satiety or contentedness and regulate binge drinking

Successful pre-clinical results in MEAI treatment for alcohol consumption

Pre-clinical trials demonstrated high safety profile in addition to a significant and immediate reduction effect on alcohol consumption.



Clearmind's First In-Human Clinical Trials: CMND-100 for AUD

Study design:

- Phase I/IIa
- The IIa will be a double-blind, placebo-controlled study
- Primary end point: to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in healthy and AUD subjects
- Secondary end point: preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate to severe AUD
- The potential effect of CMND-100 on drinking patterns and cravings in individuals with AUD in accordance with DSM-V criteria
- Oral capsules will be given once daily, for ten consecutive days
- The patients will report their drinking patterns and craving for alcohol and potentially cigarettes during the clinical trial period

Clinical Sites:

- Yale School of Medicine's Department of Psychiatry
- Johns Hopkins University School of Medicine
- IMCA, Israel

Obesity & Metabolic Syndrome

The global obesity market size is about \$29.5B and expected to grow to **\$31.7B by 2030**.

The global metabolic syndrome market was valued at \$62B in year 2021 and is expected to grow to up to **\$110.5B by 2029**.

Patent application filed with the USPTO.

Positive pre-clinical results from studies conducted at the Hebrew University of Jerusalem, Israel, with Clearmind's proprietary drug candidate, MEAI.

Source: Obesity: <https://www.globenewswire.com/news-release/2022/12/07/2569476/0/en/Obesity-Treatment-Market-Size-Worth-USD-31-7-Billion-by-2030-at-16-7-CAGR-Report-by-Market-Research-Future-MRFR.html>
Metabolic syndrom: <https://www.databridgemarketresearch.com/reports/global-metabolic-syndrome-market>


Pre-clinical results in treating Obesity

- Led by Prof. Joseph Tam, DMD, PhD, head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University's Institute for Drug Research and Dr. Saja Baraghithy, PhD.
- 3 groups of animals
- Evaluated multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns

Results for the 3rd group - high-fat diet group treated with MEAI

- Weight loss of 20%
- Reduction in fat mass and preservation of lean body mass
- Increased energy metabolism
- No effect on motivation and well-being
- Reverses obesity-related comorbidities: insulin resistance, dyslipidemia, and fatty liver.
- Significant reduction in sucrose preference supports the notion that it can dampen the hedonic value of rewarding stimuli

The data provide strong evidence for MEAI's weight-loss properties



Competitive Advantages

Focusing on alcoholism, weight loss & addictions

Clearmind is one of the few companies focused on binge behaviors and addictions: a huge untapped market. MEAI is potentially effective for alcoholism, cocaine addiction and obesity.

Novel, proprietary psychedelics

Clearmind is the sole global owner of patents around MEAI, sole developer of MEAI, and has a robust portfolio of protected intellectual property, with other NCEs (new chemical entities) such as 2-FDCK.

Accessible treatment

CMND-100 is designed to be self-administered, due to its high safety potential, and not in conjunction to psychotherapy.

Alcohol Substitute Program

The global market size for no- and low-alcohol beverages estimated at over **\$13B in 2023¹**

- Alcohol substitute was granted patents in the USA, Europe and India
- Completed most of the pre-clinical studies required for a novel-food application submission according to novel foods and food additives legislation and regulations
- Program is overseen by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh

<https://www.theiwsr.com/no-alcohol-share-of-overall-alcohol-market-expected-to-grow-to-nearly-4-by-2027/>



IP Portfolio:

29 granted patents

in major jurisdictions such as USA, EU, China and India

- Consists of **19 utility patent families** owned by the company*
- Claims include composition of matter and method of use

*Two of them jointly owned with Yissum and one jointly owned with BiLRAD

- **MEAI**: 2 mature families for **binge behaviour** regulators and **alcoholic beverage substitute**
- **MEAI + PEA**: 4 families for combination treatment for **binge behaviour**, **cocaine** addiction, **obesity** and metabolic syndrome, and **depression**
- 6 families for combinations of **PEA** with: **MDMA**, **ibogaine**, **ketamine**, **LSD**, **psilocybin** and **DMT**
- **5MAPB, 6APB**: as fail-safes for **MDMA therapy**
- **2FDCK**: for treatment of **depression** and TRD
- **3-MMC**: for treatment of **dyskinesia**, and treatment of **eating disorders**
- Novel psychedelics, methods of preparation and uses
Novel psychoactives, for treatment of mental disorders

Team of International Experts



Adi Zulloff-Shani, PhD
Chief Executive Officer



Alan Rootenberg
Chief Financial Officer



Mark Haden, MSW
VP Business Development



Gadi Levin, MBA
VP Finance



Sara Horn, PhD
Clinical and Regulatory
Affairs



Amit Shwartz, MSc
R&D Consultant



Nick Kadysh
Special Advisor
Alcohol Substitute Program



Shannon Smadella
Community Development



Yael Stav, PhD
Program Management



Mylene Touboul
Accounting Manager



Adi Varon
Controller

Highly Accomplished Board of Directors



Amitay Weiss

Chairman of the Board

Mr. Weiss served as the Chief Executive Officer of SciSparc Ltd. from August 2020 until January 2022, and since January 2022, Mr. Weiss has served as the Chairman of SciSparc's Board of Directors. In addition, Mr. Weiss currently serves as Chairman of the Board of Directors of both Automax Ltd. (TASE: AMX) and Save Foods, Inc. In 2016, Mr. Weiss founded Amity Weiss Management Ltd. and now serves as its chief executive officer. From 2001 until 2015, Mr. Weiss served as vice president of business marketing & development and in various other positions at Bank Poalei Agudat Israel Ltd. of the First International Bank of Israel group. Mr. Weiss holds a BA in economics from New England College, as well as MBA and LLB from Ono Academic College in Israel, an Israeli branch of University of Manchester.



Oz Adler

Director

Mr. Oz Adler has served as our Director since September 2021. Mr. Adler currently serves as the Chief Executive Officer and Chief Financial Officer of SciSparc Ltd. where he has served since April 2018 and between September 2017 and March 2018, he served as VP Finance of SciSparc Ltd. From December 2020 to May 2021, Mr. Adler served as the Chief Financial Officer of Medigus Ltd. Mr. Adler also worked in the audit department of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global between December 2012 and August 2017. Mr. Adler currently serves on the board of directors of numerous private and publicly traded companies, including Elbit Imaging Ltd. (TASE: EMITF), Rail Vision Ltd. (NASDAQ: RVSN), Jeffs' Brands Ltd., Polyrizon Ltd. and Charging Robotics Ltd. Mr. Adler is a certified public accountant in Israel and holds a BA degree in Accounting and Business Management from The College of Management, Israel.



Yehonatan Shachar

Director


Mr. Yehonatan Shachar has served as our Director since April 15, 2020. Mr. Shachar has served as the Chief Executive Officer of Heroic Media Ltd., a digital marketing agency that works with top Israeli e-commerce brands since February 2020. Before this role, from June 2019 until February 2021, Mr. Shachar served as the CEO of Chiron Refineries, where he led a merger with Upsellon brands. Mr. Shachar has an LLB in Law and MBA from the IDC International University in Herzliya, Israel.



Asaf Itzhaik

Director

Mr. Asaf Itzhaik has served as our Director since November 2022. Mr. Itzhaik is a seasoned international businessman in retail, BTC, BTB and real estate. He is serving as a director in Tzmiha Ltd (Israel), GIX Internet (Israel), Jeff Brands (Nasdaq), and Rani Zim (Israel). Mr. Itzhaik has 28 years of experience running an optic brand specializing in athletes.



Hila Kiron-Revach

Director

Ms. Kiron-Revach has served on the board of directors of Rail Vision Ltd. (Nasdaq: RVSN) since January 2024. Ms. Kiron-Revach has served as a member of the board of directors of Geffen Biomed Ltd. since 2014 and has been a member of the board of directors of Zmiha Investment House Ltd. since 2021. In 2021, Ms. Kiron-Revach served as a professional advisor to the chairman of the board of directors and acting secretary of Eilat Ashkelon Pipeline Company. From 2015 to 2021, Ms. Kiron-Revach served as a senior professional advisor to ministers in the Israeli government, including the minister of foreign affairs and minister of transportation. From 2012 until 2015, Ms. Kiron-Revach served as CEO of Hamil 38 – the Israeli Center for National Master Plan to Strengthen Existing Building in the Face of Earthquakes, Tama 38 Ltd. and as an attorney at Tabakman & Co. Law Firm. Ms. Kiron-Revach holds an LLB from the Netanya Academic College and is a licensed attorney in Israel.

Award-Winning Advisory Board



Prof. John Krystal

MD , Yale University, CT,
US



Prof. Fatima Stanford

MD, MPH, MPA, Harvard Medical
School, MA, US



Prof. Henry R. Kranzler

MD, PhD, University of Pennsylvania,
PA, US



Prof. Alon Friedman

MD, PhD, Dalhousie University,
Halifax, Canada



Prof. Christian Schütz

MD, PhD, University of British
Columbia, Canada



Prof. Wim van den Brink

MD, PhD, University of Amsterdam,
The Netherlands



Prof. Gabriele Fischer

MD, PhD, Medical University
Vienna, Austria



Prof. Michael Davidson

MD, Israeli Medical Centre for
Alzheimer, Israel



Prof. Joseph Tam

DMD, PhD, Hebrew University,
Israel



Prof. Gal Yadid

PhD, Bar Ilan
University, Israel

Upcoming Milestones

- › Clinical trial initiation
 - ›› CMND- 100 for treating Alcohol Use Disorder
 - ›› Initiate Israeli site and two US sites: Johns Hopkins and Yale University
- › Expanding strategic collaborations
- › Continue pre-clinical studies for obesity
- › Continue to develop MEAI-based alcohol substitute for consumer market
- › Expand IP protection, including patent for use of new proprietary molecules

Let's make history together.

Join our journey

Investor Relations

US: CMND@crescendo-IR.com

invest@clearmindmedicine.com

clearmindmedicine.com

